Navigation Links
Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
Date:5/10/2013

NEW YORK, May 10, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of a class (the "Class") of purchasers of Ventrus Biosciences, Inc. ("Ventrus" or the "Company") (NASDAQ: VTUS) securities between December 17, 2010 and June 25, 2012 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO

Ventrus is a development stage pharmaceutical company which is focused on late-stage prescription drugs for the treatment of gastrointestinal disorders, specifically hemorrhoids, anal fissures, and fecal incontinence.  Ventrus' lead products are topical treatments for hemorrhoids, which target a specific serotonin receptor.

Plaintiffs allege that, throughout the Class Period, the Company made false and/or misleading statements, as well as failed to disclose material adverse facts concerning the Company's lead product iferanserin (VEN 309) ("VEN 309").  The Company described VEN 309 as a new chemical entity for the topical treatment of symptomatic internal hemorrhoids.  The Company stated that in seven clinical studies between 1993 and 2003, VEN 309 demonstrated good tolerability and no severe adverse events while showing statistically significant improvements in bleeding, itchiness, and pain.

Specifically, during the Class Period the Company stated that it was in frequent and ongoing communications with the FDA, that clinical end points for the VEN 309 trial had been agreed to by the FDA, and that the prior results from Phase II trials of VEN 309 demonstrated the product's clinical efficacy. The Company represented its prior Phase I
'/>"/>

SOURCE Bernstein Liebhard LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
2. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
3. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
4. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
5. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
8. Echo Therapeutics Announces First Quarter 2013 Financial Results
9. Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
10. Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
11. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 16, 2015 Research and ... the addition of the "The Corporate Reputation ... - Global Edition " report to their ... a Patient Perspective, is now in its fourth ... results; published early 2015). For each annual Corporate ...
(Date:4/17/2015)... -- Sigma-Aldrich Corporation (NASDAQ: SIAL ... company, today announced the opening of its ... Cell Culture Technical Center in Singapore.  Located at ... support to meet customer needs, leveraging the Company,s ... Technical Center will significantly enhance our ability to ...
(Date:4/17/2015)... , April 17, 2015 TWi Pharmaceuticals, ... subsidiary, TWi Pharmaceuticals USA , has ... the United States.  It has been in close contact ... and expects to have its own label specialty generic ... in the U.S. pharma market. According to ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5
... I Results Offer Hope of First Highly Effective Drug in ... June 1 Roche announced today results from a Phase ... promising treatment for patients with advanced melanoma whose cancer harbours ... PLX4032 lived for a median of at least six months ...
... Eli Lilly and Company announced today that Phase ... (gemcitabine HCl for injection) to the current standard of ... at three years for women with locally advanced cervical ... commonly diagnosed women,s cancer, and the second most common ...
Cached Medicine Technology:Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 2Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 3Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 4Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released Volume ... say, “exposes a tactical shift by cyberattackers.” With everything from ... in 2014 - almost a million a day - to ... identified and patched by prominent manufacturers – as long as ... in a digital world can be fraught with peril, and ...
(Date:4/18/2015)... PHOENIX, ARIZONA – In March, Mark ... other secure destruction professionals across the United States, earned ... will now display “CSDS” as a professional title with ... National Association of Information Destruction 2015 Annual Conference began ... Of the 20 people who took the exam, Ona ...
(Date:4/17/2015)... 2015 John Evans, a Gardant affordable ... Patio from 2 p.m. to 3 p.m. on April ... Executive Ct. in Pekin, Illinois, serves older adults of ... help to maintain their independence. , Becky Baker will ... will be served during the luau. , For more ...
(Date:4/17/2015)... 2015 Riviera Magazine has ... of the Gallery of Cosmetic Surgery in Newport ... experts. The publication focused on his expertise in ... fat grafting, eyelid surgery, laser resurfacing and rhinoplasty. , ... has resulted in thousands of satisfied patients across ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... , , INDIANAPOLIS, Sept. 14 ... model to speed innovative medicines to patients, Eli Lilly ... the leaders of its Development Center of Excellence and ... markets, and Elanco animal health. These leaders will provide ...
... Oxford, UK, 14 September 2009 Elsevier, the leading ... services, announced today the launch of a new web ... Health is a website bringing together information and resources ... psychology, psychiatry and other areas of mental health. It ...
... , , Briefing is ... , , WASHINGTON, Sept. 14 ... briefing on Capitol Hill titled "Translational Research - From Bench to ... the process of development and approval for safe and effective drugs, ...
... , PLEASANTON, Calif., Sept. 14 Thoratec Corporation (Nasdaq: ... support therapies to save, support and restore failing hearts, said today ... on Tuesday, September 22. , , David V. ... update on the company beginning at 11:30 a.m., Eastern Daylight Time ...
... , WASHINGTON, Sept. 14 A call for ... certification for medical interpreters. Building upon the work the IMIA started ... now needed to undergo the final written exam pilot in support ... the subject matter expert review and rating of test items have ...
... , , NCCN is ... forum to discuss the regulatory and operational aspects of research ... improvements can be made. Scheduled for October 26 - 27 ... and panel discussions on topics that challenge the conduct of ...
Cached Medicine News:Health News:Lilly Names New Business Leaders 2Health News:Lilly Names New Business Leaders 3Health News:Lilly Names New Business Leaders 4Health News:Lilly Names New Business Leaders 5Health News:Lilly Names New Business Leaders 6Health News:Lilly Names New Business Leaders 7Health News:Lilly Names New Business Leaders 8Health News:'Translational Research: From Bench to Bedside' Capitol Hill Breakfast Briefing Hosted by the Council for American Medical Innovation 2Health News:National Certification for Medical Interpreters - Public Call for Final Written Pilot Exam 2Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: